Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis's secukinumab extends lead in IL-17 psoriatic arthritis race

This article was originally published in Scrip

Executive Summary

Novartis is planning global regulatory filings for its interleukin-17A inhibitor secukinumab (AIN457) in 2015 after reporting that it met its endpoints in two pivotal Phase III trials in psoriatic arthritis. The latest developments position it to become the first IL-17 inhibitor to reach the market for the indication. However, the lack of data comparing it with current biological therapies may limit its commercial potential.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts